BR0110473A - Métodos para inibição de proliferação e indução de apoptose em células de câncer - Google Patents
Métodos para inibição de proliferação e indução de apoptose em células de câncerInfo
- Publication number
- BR0110473A BR0110473A BR0110473-0A BR0110473A BR0110473A BR 0110473 A BR0110473 A BR 0110473A BR 0110473 A BR0110473 A BR 0110473A BR 0110473 A BR0110473 A BR 0110473A
- Authority
- BR
- Brazil
- Prior art keywords
- cancer cells
- methods
- method includes
- adenocarcinoma
- leukotriene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MéTODOS PARA INIBIçãO DE PROLIFERAçãO E INDUçãO DE APOPTOSE EM CéLULAS DE CâNCER". São descritos métodos de diminuição de proliferação de células de câncer adenocarcilioma, ou de indução de apoptose (morte celular) de células de câncer adenocarcinoma, ou de indução de diferenciação de células de câncer adenocarcinoma em células não cancerígenas. Um tal método inclui contatar as células de câncer adenocarcinoma com um composto sob condições efetivas para o composto inibir a ligação do leukotriene B4 para o receptor leukotriene B4. Em um outro método, o método inclui contatar as células de câncer adenocarcinoma com ácido benzóico 2-(2-propil-3-(3-(2-etil-4-(4-fluorofenil)-5-hidroxifenoxi)propoxi)fenoxi) ou um sal farmaceuticamente aceitável, solvato ou congênere dele. Também descritos são métodos de tratamento de adenocarcinoma em um indivíduo. Um método inclui administrar ao indivíduo uma quantidade de um composto efetivo para inibir ligação do leukotriene B4 ao receptor leukotriene B4. Um outro método inclui administrar ácido benzóico 2-(2-propil-3-(3-(2-etil-4-(4-fluorofenil)-5-hidroxifenoxi)propoxi)fenoxi) ou um sal farmaceuticamente aceitável, solvato ou congênere dele, ao indivíduo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21934400P | 2000-05-09 | 2000-05-09 | |
| PCT/US2001/040697 WO2001085166A1 (en) | 2000-05-09 | 2001-05-08 | Methods for inhibiting proliferation and inducing apoptosis in cancer cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0110473A true BR0110473A (pt) | 2003-04-01 |
Family
ID=22818912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0110473-0A BR0110473A (pt) | 2000-05-09 | 2001-05-08 | Métodos para inibição de proliferação e indução de apoptose em células de câncer |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1326605A4 (pt) |
| JP (1) | JP2003532675A (pt) |
| KR (1) | KR20030019372A (pt) |
| CN (1) | CN1237968C (pt) |
| AU (1) | AU2001261832A1 (pt) |
| BR (1) | BR0110473A (pt) |
| CA (1) | CA2408622A1 (pt) |
| MX (1) | MXPA02010974A (pt) |
| NO (1) | NO20025343L (pt) |
| NZ (1) | NZ522387A (pt) |
| WO (1) | WO2001085166A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6797723B1 (en) | 1999-11-11 | 2004-09-28 | Eli Lilly And Company | Heterocycle substituted diphenyl leukotriene antagonists |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| EP2034022A1 (en) * | 2007-09-10 | 2009-03-11 | Universite Libre De Bruxelles | Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus |
| WO2013106238A1 (en) | 2012-01-10 | 2013-07-18 | Eli Lilly And Company | Leukotriene b4 antagonist compound |
| US9775836B2 (en) | 2013-04-22 | 2017-10-03 | Tochigi Institute Of Clinical Pathology | Antitumor agent |
| KR102368958B1 (ko) | 2013-12-20 | 2022-02-28 | 노파르티스 아게 | Lta4h 억제제로서의 헤테로아릴 부탄산 유도체 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH30449A (en) * | 1991-11-25 | 1997-05-28 | Lilly Co Eli | Substituted phenyl phenol leukotriene antagonists |
| JPH10505348A (ja) * | 1994-08-31 | 1998-05-26 | イーライ・リリー・アンド・カンパニー | 耐性腫瘍の同定および治療方法 |
| US5910505A (en) * | 1997-03-21 | 1999-06-08 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma |
| WO2001034197A2 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| WO2001034198A2 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| EP1231939A2 (en) * | 1999-11-11 | 2002-08-21 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| WO2001034137A2 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
-
2001
- 2001-05-08 NZ NZ522387A patent/NZ522387A/en unknown
- 2001-05-08 WO PCT/US2001/040697 patent/WO2001085166A1/en not_active Application Discontinuation
- 2001-05-08 EP EP01935770A patent/EP1326605A4/en not_active Withdrawn
- 2001-05-08 KR KR1020027015033A patent/KR20030019372A/ko not_active Application Discontinuation
- 2001-05-08 JP JP2001581820A patent/JP2003532675A/ja active Pending
- 2001-05-08 BR BR0110473-0A patent/BR0110473A/pt not_active IP Right Cessation
- 2001-05-08 AU AU2001261832A patent/AU2001261832A1/en not_active Abandoned
- 2001-05-08 CN CNB018093299A patent/CN1237968C/zh not_active Expired - Fee Related
- 2001-05-08 CA CA002408622A patent/CA2408622A1/en not_active Abandoned
- 2001-05-08 MX MXPA02010974A patent/MXPA02010974A/es unknown
-
2002
- 2002-11-07 NO NO20025343A patent/NO20025343L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20025343L (no) | 2003-01-09 |
| CN1429111A (zh) | 2003-07-09 |
| AU2001261832A1 (en) | 2001-11-20 |
| NZ522387A (en) | 2003-09-26 |
| WO2001085166A1 (en) | 2001-11-15 |
| EP1326605A4 (en) | 2004-03-17 |
| CA2408622A1 (en) | 2001-11-15 |
| EP1326605A1 (en) | 2003-07-16 |
| JP2003532675A (ja) | 2003-11-05 |
| NO20025343D0 (no) | 2002-11-07 |
| CN1237968C (zh) | 2006-01-25 |
| MXPA02010974A (es) | 2004-09-06 |
| KR20030019372A (ko) | 2003-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200100780T2 (tr) | Cetp önleyicileri olarak 4-amino ikame edilmiş-2-ikame edilmiş-1-2,3,4- tetrahidrokinolinler | |
| ZA200005475B (en) | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with anglogenesis inhibitor. | |
| ITMI991608A0 (it) | Sonda elettrochirurgica per il trattamento di tumori mediante radiofre quenza | |
| BR9908811A (pt) | Composto, composição farmacêutica e seu uso no tratamento de mamìferos | |
| JO2283B1 (en) | Pyrimidinyl-N-Acyl-L-Phenyl Anines | |
| EG23729A (en) | N-alkanoylphenylalanine derivatives | |
| ATE279212T1 (de) | 2-methoxyestradiol-induzierte apoptosis in krebszellen | |
| BR0010524A (pt) | Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico | |
| KR970706806A (ko) | 신규한 아데노바이러스성 벡터, 패키징 세포주, 재조합 아데노바이러스와 그 방법(novel adenoviral vectors, packagning cell lines, recombinant adenoviruses and methods) | |
| MY129295A (en) | N-alkanoylphenylalanine derivatives | |
| PL333920A1 (en) | 3-pyridyl enantiomers and their application as pain-relieving agents | |
| WO1999053958A3 (en) | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor | |
| ATE246184T1 (de) | Chinoline und deren therapeutische verwendung | |
| BR0110473A (pt) | Métodos para inibição de proliferação e indução de apoptose em células de câncer | |
| DE69926251D1 (de) | Verfahren zum vernichten von tumoren und tumor-assoziierten endothelialzellen mit adenoviralen mutanten | |
| WO2001007028A3 (en) | The use of retinoid receptor antagonists in the treatment of prostate carcinoma | |
| ATE240100T1 (de) | Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten | |
| MY133682A (en) | Substituted pyrroles | |
| BR0012502A (pt) | Inibidores da expressão do gene para interleucina 5 | |
| Pintado et al. | Economic Aspects of the European Economic Space | |
| DK0912568T3 (da) | Imidazopyridiner | |
| Cheng | Ownership, control, and privatization of public enterprises | |
| Price et al. | Forecasting Shortrun Beef and Pork Supplies Using Seasonal Analysis | |
| Sadikin | Appropriate methods for closing the technology gap | |
| 李万波 et al. | Frequent Allelic Losses on Chromosomes 3 and 9q in Human Esophageal Carcinomas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO DA RPI 2016 DE 25/08/2009. |